Moberg Pharma Crecimiento futuro
Future controles de criterios 5/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Moberg Pharma de 100.9% y 63.3% respectivamente, mientras que el BPA crecerá en un 100.9% al año.
Información clave
100.9%
Tasa de crecimiento de los beneficios
100.90%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Pharmaceuticals | 37.7% |
| Tasa de crecimiento de los ingresos | 63.3% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Low |
| Última actualización | 13 May 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Actualización de narrativa • Jun 02
MOB: Dual Terbinafine Supply And Expanded Licensing Will Support Future Re Rating Potential
Analysts have adjusted their price target on Moberg Pharma to SEK14.00 from SEK13, reflecting updated assumptions around revenue growth, profit margins, discount rate and future P/E. These changes collectively reshape their view of the stock’s risk and reward profile.Actualización de narrativa • Apr 21
MOB: Dual Terbinafine Suppliers And Broader Mandate Will Support Future Re Rating Potential
Analysts now hold the fair value estimate for Moberg Pharma steady at SEK 13.0, reflecting unchanged assumptions on discount rate, revenue growth, profit margin and future P/E, and indicating that the recent review has not altered their SEK-based price target framework. What's in the News Moberg Pharma plans to propose an amendment to its articles of association at the AGM scheduled for 21 May 2026.Actualización de narrativa • Apr 06
MOB: Dual Terbinafine Sourcing Will Support Future Re Rating Potential
Analysts have reaffirmed their price target for Moberg Pharma at SEK 13.0 per share, citing unchanged views on fair value, discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News Regulators have approved an additional supplier of terbinafine for MOB-015, Moberg Pharma's drug for nail fungus, after a process that started in April 2024 (Key Developments).Actualización de narrativa • Mar 23
MOB: Dual Supplier Approval Will Support Future Re Rating Potential
Analysts have maintained their SEK fair value estimate for Moberg Pharma at SEK 13.0, with unchanged assumptions for the discount rate, revenue growth, profit margin and future P/E. This suggests their view on the company’s risk and earnings outlook remains essentially intact.Actualización de narrativa • Mar 07
MOB: Stable Assumptions And Profitability Outlook Will Support Future Re Rating
Analysts have maintained their SEK 13.0 price target for Moberg Pharma, reflecting unchanged views on fair value, discount rate, revenue growth, profit margin and future P/E assumptions. Valuation Changes Fair Value: SEK 13.0 is unchanged, with only rounding differences between the previous SEK 13 and the current SEK 13.0 figure.Actualización de narrativa • Feb 21
MOB: Higher Profitability Assumptions Will Support Re Rating Of Undervalued Shares
Analysts have adjusted their price target on Moberg Pharma to SEK 13.0. This reflects updated views on revenue growth, profit margin and a lower future P/E assumption. Valuation Changes Fair Value: SEK 13.0 is unchanged, indicating no revision to the overall price estimate.Actualización de narrativa • Feb 05
MOB: Undervalued Shares Will Rely On Stable Assumptions To Re-Rate
Analysts have kept their price target for Moberg Pharma steady at SEK 13.00. This reflects unchanged assumptions on fair value, discount rate, revenue growth, profit margin and future P/E.Actualización de narrativa • Jan 22
MOB: Europe Licensing Agreement Will Support Future Share Price Upside
Analysts have kept their price target for Moberg Pharma steady at SEK 13.0. This reflects unchanged assumptions on fair value, discount rate, revenue growth, profit margin and future P/E despite the latest review of their model inputs. What's in the News Karo Healthcare AB and Moberg Pharma AB have signed an exclusive licensing agreement for the commercialisation of MOB-015 in 19 European markets, covering a population of about 500 million people (Key Developments).Actualización de narrativa • Jan 08
MOB: Europe Licensing Agreement Will Support Strong Future Share Price Upside
Analysts have maintained their price target on Moberg Pharma at SEK 13.0, with unchanged assumptions on fair value, discount rate, revenue growth, profit margin and future P/E. This indicates their core view on the stock remains intact for now.Actualización de narrativa • Dec 16
MOB: Exclusive European Licensing Deal Will Drive Strong Future Share Upside
Analysts have marginally adjusted their price target on Moberg Pharma, reiterating a fair value of SEK 13.0 per share as they maintain their assumptions for discount rate, revenue growth, profit margins, and future valuation multiples. What's in the News Karo Healthcare AB signs an exclusive licensing agreement with Moberg Pharma for the commercialisation of MOB-015 across 19 European markets, including all major EU countries and the United Kingdom, ensuring a coordinated launch under the Lamisil brand (Company announcement) The licensing deal grants Karo responsibility for marketing, distribution, and sales in 11 countries where MOB-015 is already approved but not yet launched, accelerating the product’s European rollout (Company announcement) MOB-015, a new topical terbinafine formulation, demonstrates mycological cure rates of 76 percent in registration studies, delivering efficacy on par with oral treatment and addressing historical challenges in penetrating the nail (Company announcement) The agreement provides Moberg Pharma with access to a total addressable population of about 500 million people in Europe, significantly expanding the commercial potential of MOB-015 (Company announcement) Valuation Changes Fair Value: Unchanged at SEK 13.0 per share, reflecting a stable outlook for Moberg Pharma’s intrinsic valuation.Actualización de narrativa • Dec 02
MOB: Exclusive Licensing Deal Will Unlock Major European Market Launches
Analysts have maintained their price target for Moberg Pharma at SEK 13.00. This reflects continued confidence in the company's earnings outlook and growth potential.Actualización de narrativa • Nov 18
MOB: Licensing Agreement Will Drive Expansion Across Europe This Year
Analysts have raised their price target for Moberg Pharma from SEK 11 to SEK 13. This change reflects updated forecasts that consider notable shifts in anticipated revenue growth, profitability, and market conditions.Artículo de análisis • Nov 07
We're Not Worried About Moberg Pharma's (STO:MOB) Cash Burn
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Artículo de análisis • May 16
Shareholders Will Probably Hold Off On Increasing Moberg Pharma AB (publ)'s (STO:MOB) CEO Compensation For The Time Being
Key Insights Moberg Pharma's Annual General Meeting to take place on 22nd of May Total pay for CEO Anna Ljung includes...
Nueva narrativa • Apr 13
Norway Expansion And EU Approvals Will Strengthen Future Position
Expansion in Norway and obtaining EU approvals bolster revenue potential and support Moberg Pharma's European growth strategy.Artículo de análisis • Feb 12
Companies Like Moberg Pharma (STO:MOB) Can Afford To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Artículo de análisis • Sep 14
We're Hopeful That Moberg Pharma (STO:MOB) Will Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Artículo de análisis • May 08
Moberg Pharma AB (publ)'s (STO:MOB) CEO Will Probably Find It Hard To See A Huge Raise This Year
Key Insights Moberg Pharma to hold its Annual General Meeting on 14th of May Salary of kr1.99m is part of CEO Anna...Artículo de análisis • Nov 16
Moberg Pharma (STO:MOB) Will Have To Spend Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Artículo de análisis • Jan 17
Will Moberg Pharma (STO:MOB) Spend Its Cash Wisely?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Artículo de análisis • Dec 03
Read This Before Selling Moberg Pharma AB (publ) (STO:MOB) Shares
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2028 | 95 | 27 | N/A | 34 | 1 |
| 12/31/2027 | 56 | 9 | N/A | 15 | 1 |
| 12/31/2026 | 23 | -18 | N/A | -16 | 1 |
| 3/31/2026 | 15 | -26 | -45 | -12 | N/A |
| 12/31/2025 | 14 | -27 | -61 | -17 | N/A |
| 9/30/2025 | 12 | -258 | -71 | -16 | N/A |
| 6/30/2025 | 12 | -255 | -80 | -14 | N/A |
| 3/31/2025 | 13 | -251 | -92 | -21 | N/A |
| 12/31/2024 | 10 | -255 | -90 | -16 | N/A |
| 9/30/2024 | 9 | -18 | -115 | -27 | N/A |
| 6/30/2024 | 5 | -23 | -134 | -33 | N/A |
| 3/31/2024 | 1 | -23 | -139 | -31 | N/A |
| 12/31/2023 | N/A | -21 | -157 | -33 | N/A |
| 9/30/2023 | N/A | -18 | -134 | -29 | N/A |
| 6/30/2023 | 0 | -16 | -105 | -21 | N/A |
| 3/31/2023 | 0 | -16 | -96 | -16 | N/A |
| 12/31/2022 | 0 | -16 | -85 | -17 | N/A |
| 9/30/2022 | 0 | -17 | -75 | -14 | N/A |
| 6/30/2022 | N/A | -16 | -70 | -12 | N/A |
| 3/31/2022 | N/A | -16 | -56 | -7 | N/A |
| 12/31/2021 | N/A | -16 | -47 | -15 | N/A |
| 9/30/2021 | 34 | 8 | -44 | -9 | N/A |
| 6/30/2021 | 34 | 7 | -46 | -12 | N/A |
| 3/31/2021 | 34 | 5 | -58 | -16 | N/A |
| 12/31/2020 | 34 | 7 | -52 | -10 | N/A |
| 6/30/2020 | 50 | 20 | -47 | 4 | N/A |
| 6/30/2019 | 31 | -8 | N/A | -76 | N/A |
| 3/31/2019 | 455 | 31 | N/A | 88 | N/A |
| 12/31/2018 | 5 | -28 | N/A | 74 | N/A |
| 9/30/2018 | 341 | 9 | N/A | 87 | N/A |
| 6/30/2018 | 340 | 19 | N/A | 109 | N/A |
| 3/31/2018 | 334 | 6 | N/A | 68 | N/A |
| 12/31/2017 | 439 | 11 | N/A | 54 | N/A |
| 9/30/2017 | 438 | -1 | N/A | 30 | N/A |
| 6/30/2017 | 434 | 0 | N/A | -44 | N/A |
| 3/31/2017 | 369 | 35 | N/A | -17 | N/A |
| 12/31/2016 | 334 | 33 | N/A | -18 | N/A |
| 9/30/2016 | 299 | 36 | N/A | -21 | N/A |
| 6/30/2016 | 261 | 32 | N/A | 12 | N/A |
| 3/31/2016 | 282 | 9 | N/A | 32 | N/A |
| 12/31/2015 | 286 | 26 | N/A | 31 | N/A |
| 9/30/2015 | 276 | 25 | N/A | 34 | N/A |
| 6/30/2015 | 260 | 20 | N/A | 30 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que MOB sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2%).
Beneficios vs. Mercado: Se prevé que MOB sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.
Beneficios de alto crecimiento: Se espera que MOB sea rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (63.3% al año) de MOB crezcan más rápidamente que los del mercado Swedish (0.02% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos (63.3% al año) de MOB crezcan más rápidamente que un 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de MOB se prevé que sea elevada dentro de 3 años.
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/06/14 19:50 |
| Precio de las acciones al final del día | 2026/06/12 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Moberg Pharma AB (publ) está cubierta por 4 analistas. 1 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Bjorn Rydell | ABG Sundal Collier Sponsored |
| Klas Pyk | Nordea Markets |
| Mats Hyttinge | Redeye |